Evidence map›Paper›PMID 33682011›Full record

ArticleSurgery today2021

Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.

Jin Moriyama, Yoko Oshima, Tatsuki Nanami, Takashi Suzuki, Satoshi Yajima, Fumiaki Shiratori, Kimihiko Funahashi, Hideaki Shimada

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jin MoriyamaDepartment of Clinical Oncology, Toho University Graduate School of Medicine, Ota-ku, Tokyo, Japan.
Yoko OshimaDepartment of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
Tatsuki NanamiDepartment of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
Takashi SuzukiDepartment of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
Satoshi YajimaDepartment of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
Fumiaki ShiratoriDepartment of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
Kimihiko FunahashiDepartment of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
Hideaki ShimadaDepartment of Clinical Oncology, Toho University Graduate School of Medicine, Ota-ku, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.ORCID http://orcid.org/0000-0002-1990-8217
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe evaluated the clinical impact of the carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) values at the time of recurrence in gastric cancer patients.

methodsAmong 790 patients with R0 resected gastric cancer without neoadjuvant therapy between 2004 and 2017, 89 recurrence cases were retrospectively evaluated. The clinical impact of CEA and CA19-9 values on recurrence sites and post-recurrent prognosis were evaluated using univariate and multivariate analyses.

resultsThe positive rates of CEA and CA19-9 at recurrence were significantly higher than the preoperative positive rates (CEA, 56% vs 24%; CA19-9, 37% vs 15%). Although CA19-9-positive patients at recurrence exhibited a poor survival, the difference was not significant. The positive rates of CEA at liver or lymph node recurrence were significantly higher than the preoperative positive rates. The positive rate of CA19-9 at peritoneal recurrence was significantly higher than the preoperative positive rate. CA19-9-positive patients at recurrence exhibited worse prognosis than CA19-9-negative patients, although the difference was not significant. At lymph node recurrence, CA19-9-positive patients exhibited a significantly worse survival than CA19-9-negative patients.

conclusionIn recurrent gastric cancer, the positive status of CA19-9 at recurrence might have a negative prognostic impact after recurrence; particularly, in patients with lymph node recurrence.

Indexed as

Neoplasm Recurrence, LocalBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenFemaleGastrectomyHumansLymph Node ExcisionMalePrognosisRetrospective StudiesStomach NeoplasmsSurvival RateBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenCA19-9CEAGastric cancerPrognosisRecurrence

Identifiers

PMID33682011
OpenAlexW3134630615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.